Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -3.0959752322 | 3.23 | 3.3388 | 3 | 112134 | 3.09015349 | CS |
4 | -0.02 | -0.634920634921 | 3.15 | 3.49 | 2.99 | 81843 | 3.18156596 | CS |
12 | 0.11 | 3.64238410596 | 3.02 | 3.62 | 2.93 | 104166 | 3.27622575 | CS |
26 | -1.76 | -35.9918200409 | 4.89 | 4.9588 | 2.88 | 138493 | 3.52288678 | CS |
52 | -13.56 | -81.2462552427 | 16.69 | 17 | 2.88 | 308266 | 4.16074484 | CS |
156 | -13.56 | -81.2462552427 | 16.69 | 17 | 2.88 | 308266 | 4.16074484 | CS |
260 | -13.56 | -81.2462552427 | 16.69 | 17 | 2.88 | 308266 | 4.16074484 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.